Personalized tapering of adalimumab for rheumatoid arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study tests if checking the amount of adalimumab (a biologic drug) in your blood can help doctors safely lower your dose. If you have had rheumatoid arthritis under control for at least 6 months, this trial may help you take less medication while keeping symptoms away.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have rheumatoid arthritis that has been in remission (quiet) for at least 6 months.
- You have been taking adalimumab (brand name Humira) for at least 6 months, either every 2 weeks or every 3 weeks.
- You are not currently pregnant, breastfeeding, or planning to become pregnant in the next 15 months.
- You have not taken prednisone (a steroid) for your RA in the last 6 months.
- You do not have fibromyalgia along with your RA.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized approach to find which of four biologic drugs works best for you if methotrexate didn't help or caused side effects. You'll get each drug in turn and track your symptoms to find your best match.
This Phase 4 trial studies whether immune-modulator medicines improve symptoms and function in people with rheumatoid arthritis who have knee problems. It may also compare responses in osteoarthritis and healthy volunteers, depending on the group you fit.
This study tests whether a lower dose of adalimumab (a biologic medication) can keep controlling chronic non-infectious uveitis (eye inflammation that is not caused by an infection) after it has been well-controlled for a long time. If you have stable eye inflammation and have been on the standard adalimumab dose (40 mg every 2 weeks) for at least 24 weeks, this trial may be suitable for you.
This study compares two different schedules for reducing prednisone (a steroid) in people with rheumatoid arthritis who are also taking another standard arthritis medicine. The goal is to find the safest and most effective way to taper off steroids without causing a flare-up.
This trial tests a step-by-step plan for treating rheumatoid arthritis when current medicines aren’t controlling the disease. It compares how well a targeted approach works by adjusting treatment for people who need a TNF inhibitor.
This study follows people with rheumatoid arthritis (RA) who have achieved remission—meaning their disease is well-controlled—to see how safely doctors can reduce or stop their medications over time. You would be monitored regularly to ensure your RA stays in remission.
Hear when a new Arthritis, Rheumatoid trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.